Dieckmann K P, Classen J, Souchon R, Loy V
Urologische Abteilung, Albertinen-Krankenhaus Hamburg.
Wien Klin Wochenschr. 2001 Jan 15;113(1-2):7-14.
Testicular intraepithelial neoplasia (TIN; also called carcinoma in situ of the testis) is the uniform precursor of testicular germ cell tumors. There is general agreement on the biological significance of TIN, however, the treatment is still a matter of dispute. The present review summarizes the treatment options currently available. In general, the management of TIN has to be adapted to the particular clinical situation of the patient. Eradication of TIN usually implies the loss of fertility. Therefore, fertility aspects should be considered before any kind of treatment is employed. Usually, patients with TIN have only small residual potential of fertility. Nonetheless, individual patients may qualify for sperm banking or cryopreservation of testicular tissue for future sperm extraction (TESE) and assisted fertilization. The most common clinical situation is the case of contralateral TIN in the presence of unilateral testicular cancer. Low dose radiotherapy to the testis with 18 Gy is the standard management option in these patients. The same procedure may be applied to solitary testicles after partial orchiectomy for germ cell tumors. During follow-up, testosterone levels should be evaluated every six months. If chemotherapy is required due to metastatic disease of the primary tumor management of TIN should be deferred. After chemotherapy 30% of TIN cases will persist and approximately 42% will recur in the later course. Repeat biopsy should be done six months after completion of chemotherapy or later. Only in cases with persistent TIN additional radiotherapy should be administered. If one testicle is afflicted with TIN while the other testis is in healthy condition (conceivable in infertility cases or patients with primary extragonadal germ cell tumors), then the TIN-bearing testis should be excised. Radiotherapy is not feasible in these cases because of shielding problems with the healthy testis.
睾丸上皮内瘤变(TIN;也称为睾丸原位癌)是睾丸生殖细胞肿瘤的统一前驱病变。关于TIN的生物学意义已达成普遍共识,然而,其治疗仍存在争议。本综述总结了目前可用的治疗选择。一般来说,TIN的管理必须根据患者的具体临床情况进行调整。根除TIN通常意味着生育能力的丧失。因此,在采用任何治疗方法之前都应考虑生育方面的问题。通常,患有TIN的患者生育潜力仅存很小一部分。尽管如此,个别患者可能有资格进行精子库储存或冷冻保存睾丸组织,以备将来提取精子(睾丸精子提取术)和辅助受精。最常见的临床情况是单侧睾丸癌患者对侧出现TIN。对睾丸进行18 Gy的低剂量放疗是这些患者的标准管理选择。对于因生殖细胞肿瘤行部分睾丸切除术后的孤立睾丸,也可采用相同的方法。在随访期间,应每六个月评估一次睾酮水平。如果由于原发性肿瘤的转移性疾病需要化疗,则应推迟TIN的管理。化疗后,30%的TIN病例将持续存在,约42%将在后期复发。化疗完成后六个月或更晚应进行重复活检。仅在TIN持续存在的情况下,才应给予额外的放疗。如果一个睾丸患有TIN而另一个睾丸健康(在不育病例或原发性性腺外生殖细胞肿瘤患者中可能出现),则应切除患TIN的睾丸。由于健康睾丸的屏蔽问题,这些病例中放疗不可行。